Engineered myeloid precursors differentiate into osteoclasts and resorb heterotopic ossification in mice
In summary, these data con rm the ability of engineered myeloid precursors to differentiate into OCs and resorb HO <i>in vivo</i> paving the way for OC delivery as a promising approach for HO treatment.
Authors
- Mei Y. Speer
- Cecilia M. Giachelli (ORCID: https://orcid.org/0000-0002-6387-5993)
- Subramanian Dharmarajan (ORCID: https://orcid.org/0000-0003-3016-2484)
- Steven D. Bain (ORCID: https://orcid.org/0000-0002-2287-5874)
- Cameron Rementer
- Marta Scatena (ORCID: https://orcid.org/0000-0002-2288-6020)
- Worakanya Buranaphatthana (ORCID: https://orcid.org/0000-0002-6152-5949)
- Elizabeth Leber
- Apichai Yavirach (ORCID: https://orcid.org/0000-0003-3827-3963)
- Bruce Sangiorzan
- Alexander Blümke
- Philip A. Walczak
- Kat Pierce
Institutions
- University of Washington (US)
- Heidelberg University (DE)
- University Hospital Heidelberg (DE)
- University Medical Centre Mannheim (DE)
- Chiang Mai University (TH)
Publication Details
- Journal
- Frontiers in Bioengineering and Biotechnology
- Published
- 2024-11-22
- DOI
- https://doi.org/10.3389/fbioe.2024.1491962
- Citations
- 1
- Primary Topic
- Heterotopic Ossification and Related Conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.47
Funders
- U.S. Department of Defense
- National Institutes of Health